Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1666582

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that alternatives to elvanse and guanfacine are available for people with ADHD.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	203938
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), including elvanse and guanfacine. Some issues have now been resolved. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. These issues are expected to resolve by the end of December 2023.</p><p>We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p><p>We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203939 question first answered 26/10/2023 06:15:56 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1666583

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that there are adequate supplies of (a) elvanse and (b) guanfacine.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	203939
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), including elvanse and guanfacine. Some issues have now been resolved. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. These issues are expected to resolve by the end of December 2023.</p><p>We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p><p>We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203938 question first answered 26/10/2023 06:15:57 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1666059

registered interest
date	19/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ultrasonics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the potential impact of the use of (a) MR-guided focused ultrasound (MRgFUS) and (b) non-MRgFUS treatments for NHS patients on their [levels of?] wellbeing.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	203584
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>We have not made a specific assessment. On the National Health Service, transcranial magnetic resonance guided focused ultrasound thalamotomy is only recommended for the treatment of medication-refractory essential tremor in patients that are not eligible for deep brain stimulation and within the criteria set out in the NHS’ guidance, which is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/transcranial-magnetic-resonance-guided-focused-ultrasound-thalamotomy-for-treatment-of-medication-refractory-essential-tremor/" target="_blank">https://www.england.nhs.uk/publication/transcranial-magnetic-resonance-guided-focused-ultrasound-thalamotomy-for-treatment-of-medication-refractory-essential-tremor/</a></p><p> </p> answering member constituency Colchester answering member printed Will Quince question first answered 23/10/2023 14:23:09 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1650054

registered interest
date	04/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will provide a breakdown of how the £50 million funding ring-fenced for research into Motor-Neurone Disease is to be spent.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	192421
answer	answer is ministerial correction date of answer 07/07/2023 answer text <p>Funding for motor neurone disease research has always been available via open competition. In 2021/22, the National Institute for Health and Care Research (NIHR) spent £3.8 million on MND research, and UK Research and Innovation (UKRI), through the Medical Research Council (MRC), spent around £10.8 million.</p><p>The Government has committed to make at least £50 million available for MND research over the next five years, ending in March 2027. In June 2023, we set out how £36.5 million of the £50 million pledged to MND research is now allocated to cutting-edge researchers.</p><p>The £36.5 million package includes, £7m of new research grants allocated by the MRC, including three fellowships and four research grants. £8 million for early phase clinical research for MND, speeding up innovative new treatments for patients through the NIHR Biomedical Research Centres. This is made up of a £4.7 million investment in a collaboration of UK researchers who will take forward an early phase platform trial to screen for drugs which have the potential to be successful in clinical trials. It also includes a further £3.25 million investment to train a new group of MND researchers to support future research and £12.5 million to support the best discovery science at the UK Dementia Research Institute.</p><p>In June 2022, a £4.25 million MND collaborative partnership was launched to bring the MND research community together, for leading researchers to collaborate on accelerating delivery of new treatments, with £1 million contribution from Government. NIHR is contributing a further £2 million to the MND Collaborative Partnership led by LifeArc to focus on gathering and analysing existing data on the condition to explore the underlying causes of MND and help develop breakthrough new treatments.</p><p>£6 million fund, £3 million from MRC and £3 million from NIHR, for a translational accelerator investment which will connect the UK Dementia Research Institute, the MND collaborative partnership, and the UK Dementias Platform.</p><p>To support this work, the Government published a joint NIHR MRC Highlight Notice inviting outstanding researchers across the academic and life science sector to submit applications to an open call. For the remainder of the £50 million, we are encouraging all researchers to apply for this funding via open call.</p> answering member constituency Colchester answering member printed Will Quince question first answered 07/07/2023 13:43:50 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1650055

registered interest
date	04/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merit of funding research into low-dose interleukin 2 treatments for Motor Neurone Disease.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	192422
answer	answer is ministerial correction date of answer 07/07/2023 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health, including research into treatments such as low-dose interleukin 2. The NIHR does not ring-fence funds for expenditure on particular topics. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p><p>The Government is determined to accelerate research to find a cure and develop innovative treatments which will slow or stop motor neurone disease (MND) and improve people’s lives. The Government has committed to make at least £50 million available for MND research over the next five years, ending in March 2027. In 2021/22, NIHR spent £3.8 million on MND research, and UK Research and Innovation, through the Medical Research Council, spent around £10.8 million.</p> answering member constituency Colchester answering member printed Will Quince question first answered 07/07/2023 13:15:22 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1650056

registered interest
date	04/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much of the £50million ring-fenced funding for Motor-Neurone Disease research (a) has been and (b) is planned to be spent on researching interleukin 2 therapies for that disease.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	192423
answer	answer is ministerial correction date of answer 07/07/2023 answer text <p>The Government has committed to make at least £50 million available for motor neurone disease (MND) research over the next five years, ending in March 2027. In June 2023, the Government set out how £36.5 million of the £50 million pledged to MND research is now allocated to cutting-edge researchers. Research activities funded by the Department via the National Institute for Health and Care Research do not include research on interleukin 2 therapies for MND.</p><p>For the remainder of the £50 million, the Government is encouraging all researchers to apply for this funding via open call. The NIHR welcomes funding applications for research into any aspect of human health, including research into therapies such as interleukin 2. NIHR does not ring-fence funds for expenditure on particular topics. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p> answering member constituency Colchester answering member printed Will Quince question first answered 07/07/2023 13:13:49 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1650057

registered interest
date	04/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what (a) therapies and (b) treatments his Department is funding to treat Motor Neurone Disease.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	192424
answer	answer is ministerial correction date of answer 10/07/2023 answer text <p>Patients with motor neurone disease (MND) require access to a range of NHS services. Riluzole is the only drug licensed in the UK to slow the progression of MND. Riluzole was recommended by the National Institute for Care Excellence (NICE) in 2001 for the treatment of individuals with the amyotrophic lateral sclerosis (ALS) form of MND within its licensed indications, which are to extend life or the time to mechanical ventilation for individuals with ALS. NICE is currently evaluating a potential new treatment, Tofersen, for ALS caused by SOD1 gene mutations and, subject to licensing, expects to publish guidance in July 2024.</p><p>NHS England commissions the specialised care and treatment that patients with MND may receive from the specialised neurological treatment centres across England. Integrated Care Boards are responsible for the commissioning of the non-specialised elements of treatment and care patients with MND may require. Funding decisions for both the specialised and non-specialised elements of patients’ care are made in line with local needs and priorities.</p> answering member constituency Colchester answering member printed Will Quince question first answered 10/07/2023 13:58:32 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1650058

registered interest
date	04/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is providing funding to the Brighton and Sussex Medical School to develop a treatment for Motor Neurone Disease.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	192425
answer	answer is ministerial correction date of answer 10/07/2023 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health, including research into treatments for motor neurone disease (MND). NIHR does not ring-fence funds for expenditure on particular topics. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p><p>The Department, via the NIHR is not providing funding to the Brighton and Sussex Medical School to develop a treatment for MND.</p> answering member constituency Colchester answering member printed Will Quince question first answered 10/07/2023 14:11:59 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1650059

registered interest
date	04/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nurses: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of the restoration of the nurse’s bursary.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	192426
answer	answer is ministerial correction date of answer 07/07/2023 answer text <p>The Student Loans Company provides the primary funding support package for students in further education. Student loan repayments are unlike commercial loans, with built-in protections, including repayments linked to income and not based on interest rates or the amount borrowed, and with outstanding loan amounts written off after 30 years. Student loans are subsidised by the taxpayer, this is a conscious investment in the skills and people of this country.</p><p>In addition to this, eligible nursing students have access to supplementary funding support via the NHS Learning Support Fund, which offers a non-repayable grant of £5,000 per academic year plus additional grants and supports depending on their circumstances.</p> answering member constituency Colchester answering member printed Will Quince question first answered 07/07/2023 13:48:04 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore

1611632

registered interest
date	18/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Labour Turnover
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve retention of the NHS workforce.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	181176
answer	answer is ministerial correction date of answer 25/04/2023 answer text <p>Retention within the National Health Service is a complex issue and decisions to leave are taken for a multitude of reasons. The NHS People Plan and the People Promise focus on improving the retention of NHS staff by prioritising staff health and wellbeing. We have set out a comprehensive range of actions to improve staff retention which focus on creating a more modern, compassionate and inclusive NHS culture by strengthening health and wellbeing, equality and diversity, culture and leadership and flexible working.</p><p>Building on this work, the NHS Retention Programme seeks to understand why staff leave, resulting in targeted interventions to support staff to stay whilst keeping them well. To bolster current support, each NHS organisation is prioritising the delivery of five high impact actions that will impact on early-career, experienced and late-career staff, improving the experience and retention of nursing and midwifery staff.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/04/2023 10:11:33 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore